Although the analysis of liquid biopsy components such as tumor exosomes and circulating cell-free RNA are still at an early stage [26], future evaluation of alterations of the cyclin E1-CDK2 axis in liquid biopsies of ER+/HER2− ABC patients is promising. The gene discussed is ESR1; the disease is neoplasm.